4 results about "Aspartate protease" patented technology

The present application relates to a kind of preparation method of immunoglobulin powder and its application, the preparation method includes the following steps: collecting bovine colostrum, using cell survival technology is frozen;Frozen bovine colostrum is thawed, carries out milk fat separation, and obtains defatted bovine colostrum;Defatted bovine colostrum and composite rennet are mixed and are curdled, and then broken, obtain whey;The composite rennet includes aspartic protease, papain and bromelain;Whey is ultrafiltrated, and immunoglobulin solution is obtained;Immunoglobulin solution is vacuum freeze-dried, and the immunoglobulin powder is obtained.The preparation method provided by the present application is low temperature all the way, the activity of immunoglobulin is retained to the greatest extent, the use of composite rennet solves the problem of curd failure, and each link cooperates to improve the curd effect, realizes the preparation of high-efficiency, high-purity and high-quality immunoglobulin powder.

This disclosure relates to a drug delivery system comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, a tumor necrosis factor-α (TNF-α) or TNF receptor (TNFR) inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease (caspase) inhibitor, including any combination of these compounds and, optionally, a sustained delivery component. This type of drug delivery system can be used to treat a medical condition such as an inherited or age-related choroid, retina, optic nerve disorder, or optic nerve degeneration; an otic disorder; a neurologic or CNS disorder; or a related condition; or a condition related to occlusion or obstruction of a blood vessel or blood circulation such as a stroke, myocardial or renal infarction. Medicaments, methods of manufacturing medicaments, kits, and other related products or methods are also described.

The disclosure relates to methods for enhancing production of a heterologous protein in a plant or plant cell by inhibiting aspartic protease AED3-1. Also provided are plants and plant cells with enhanced production of a heterologous protein, wherein the plant or plant cell has reduced or loss of function of AED3-1. Further provided are shRNAs and vectors for use in enhancing production of a heterologous protein in a plant or plant cell.

The application discloses application of 1-aminocyclopropane carboxylic acid in preparation of a melanoma treatment drug and relates to the field of medicinal chemistry. The 1-aminocyclopropane carboxylic acid of the application effectively slows down melanoma cell proliferation by activating a cysteine aspartate protease cascade signal pathway, inhibiting extracellular regulatory protein kinase 1 / 2, phosphorylated protein kinase B and B lymphocyte tumor-2 signal pathways, and significantly reducing tumor tissue volume and mass, thereby playing an obvious curative effect.